Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa

被引:0
|
作者
Zorina, Alla [1 ,2 ]
Zorin, Vadim [1 ,2 ]
Isaev, Artur [1 ]
Kudlay, Dmitry [3 ,4 ]
Manturova, Natalia [5 ,6 ]
Ustugov, Andrei [5 ,6 ]
Kopnin, Pavel [7 ]
机构
[1] Artgen Biotech, Moscow 119333, Russia
[2] Skincell LLC, Moscow 119333, Russia
[3] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Dept Pharmacol, Moscow 119991, Russia
[4] Lomonosov Moscow State Univ, Dept Pharmacognosy, Ind Pharm, Moscow 119992, Russia
[5] Pirogov Russian Natl Res Med Univ, Dept Plast & Reconstruct Surg Cosmetol & Cell Tech, Moscow 117997, Russia
[6] JSC Plast Surg & Cosmetol Inst, Moscow 125047, Russia
[7] NN Blokhin Natl Med Res Ctr Oncol, Sci Res Inst Carcinogenesis, Moscow 115522, Russia
基金
俄罗斯科学基金会;
关键词
epidermolysis bullosa; skin; treatment; gene and cell therapy; stem cells; gene delivery; study outcomes; MESENCHYMAL STEM-CELLS; BONE-MARROW-TRANSPLANTATION; RETROVIRAL DNA INTEGRATION; UMBILICAL-CORD BLOOD; VII COLLAGEN; STROMAL CELLS; MOUSE MODEL; FIBROBLAST THERAPY; CULTURED SKIN; COL7A1;
D O I
10.3390/ijms251910270
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This detailed review describes innovative strategies and current products for gene and cell therapy at different stages of research and development to treat recessive dystrophic epidermolysis bullosa (RDEB) which is associated with the functional deficiency of collagen type VII alpha 1 (C7) caused by defects in the COL7A1 gene. The use of allogenic mesenchymal stem/stromal cells, which can be injected intradermally and intravenously, appears to be the most promising approach in the field of RDEB cell therapy. Injections of genetically modified autologous dermal fibroblasts are also worth mentioning under this framework. The most common methods of RDEB gene therapy are gene replacement using viral vectors and gene editing using programmable nucleases. Ex vivo epidermal transplants (ETs) based on autologous keratinocytes (Ks) have been developed using gene therapy methods; one such ET successively passed phase III clinical trials. Products based on the use of two-layer transplants have also been developed with both types of skin cells producing C7. Gene products have also been developed for local use. To date, significant progress has been achieved in the development of efficient biomedical products to treat RDEB, one of the most severe hereditary diseases.
引用
收藏
页数:29
相关论文
共 50 条
  • [21] Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa
    Naso, Gaetano
    Petrova, Anastasia
    BRITISH MEDICAL BULLETIN, 2020, 136 (01) : 30 - 45
  • [22] SQUAMOUS-CELL CARCINOMA AND RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA
    FOUREL, E
    CLAUDY, AL
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1992, 119 (08): : 563 - 565
  • [23] Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9
    Takashima, Shota
    Shinkuma, Satoru
    Fujita, Yasuyuki
    Nomura, Toshifumi
    Ujiie, Hideyuki
    Natsuga, Ken
    Iwata, Hiroaki
    Nakamura, Hideki
    Vorobyev, Artem
    Abe, Riichiro
    Shimizu, Hiroshi
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (08) : 1711 - +
  • [24] Understanding the Pathogenesis of Recessive Dystrophic Epidermolysis Bullosa Squamous Cell Carcinoma
    South, Andrew P.
    O'Toole, Edel A.
    DERMATOLOGIC CLINICS, 2010, 28 (01) : 171 - +
  • [25] Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa
    Kiritsi, Dimitra
    Garcia, Marta
    Brander, Renske
    Has, Cristina
    Meijer, Rowdy
    Jose Escamez, Maria
    Kohlhase, Juergen
    van den Akker, Peter C.
    Scheffer, Hans
    Jonkman, Marcel F.
    del Rio, Marcela
    Bruckner-Tuderman, Leena
    Pasmooij, Anna M. G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (08) : 2097 - 2104
  • [26] Gene Therapy for Epidermolysis Bullosa
    Marinkovich, M. Peter
    Tang, Jean Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (06) : 1221 - 1226
  • [27] Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa
    Oever, Michael Vanden
    Twaroski, Kirk
    Osborn, Mark J.
    Wagner, John E.
    Tolar, Jakub
    PEDIATRIC RESEARCH, 2018, 83 (01) : 318 - 324
  • [28] Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa
    Petrof, Gabriela
    Lwin, Su M.
    Martinez-Queipo, Magdalena
    Abdul-Wahab, Alya
    Tso, Simon
    Mellerio, Jemima E.
    Slaper-Cortenbach, Ineke
    Boelens, Jaap J.
    Tolar, Jakub
    Veys, Paul
    Ofuya, Mercy
    Peacock, Janet L.
    Martinez, Anna E.
    McGrath, John A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (09) : 2319 - 2321
  • [29] Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa
    Twaroski, K.
    Eide, C.
    Riddle, M. J.
    Xia, L.
    Lees, C. J.
    Chen, W.
    Mathews, W.
    Keene, D. R.
    McGrath, J. A.
    Tolar, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (06) : 1247 - 1253
  • [30] Innovative Therapeutic Strategic for Recessive Dystrophic Epidermolysis Bullosa
    Larcher, F.
    Del Rio, M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2015, 106 (05): : 376 - 382